Compass Therapeutics, Inc. — Form 10-Q Summary
Business context and reporting period
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing antibody-based therapeutics targeting angiogenesis and the immune system. The filing covers the unaudited quarter ended March 31, 2022, and was filed May 9, 2022. The company has no product revenue and remains dependent on equity financing and other capital sources.
Clinical-stage programs include CTX-009, CTX-471 and CTX-8371. CTX-009 is being developed for advanced biliary tract cancer and other solid tumors; CTX-471 is in a Phase 1b study; and CTX-8371 is in IND-enabling development.
Key financial metrics
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No product revenue |
| Research and development expense | $4.4 million | $4.7 million | Down $0.3 million, or 6% |
| General and administrative expense | $2.8 million | $2.6 million | Up $0.1 million, or 5% |
| Total operating expenses | $7.2 million | $7.3 million | Down $0.2 million |
| Net loss | $7.2 million | $7.4 million | Improved by $0.3 million |
| Net loss per share | $0.07 | $0.14 | Improved; share count increased materially |
| Net cash used in operating activities | $7.9 million | $5.6 million | Use increased by $2.3 million |
| Cash and cash equivalents at period end | $136.4 million | $39.8 million | Higher than prior-year period |
| Accumulated deficit at period end | $240.8 million | Not provided in the filing excerpt | — |
The filing does not present a meaningful operating margin because the company has no revenue. Operating loss was $7.2 million. Other income was $20 thousand, compared with other expense of $83 thousand in the prior-year quarter. No income tax expense was recorded.
At March 31, 2022, total assets were $146.6 million, total liabilities were $12.1 million and stockholders’ equity was $134.5 million. Debt-related borrowings had been extinguished in the fourth quarter of 2021; remaining material financial obligations include operating lease liabilities of $3.8 million and a $6.0 million accrued milestone payment to ABL Bio related to CTX-009.
Material changes versus the prior comparable period
- Research and development expense declined 6%, primarily because of lower manufacturing expense. Program spending increased for CTX-009 and CTX-471 but decreased for CTX-8371 and unallocated activities.
- General and administrative expense increased 5%, including higher stock-based compensation.
- Net loss improved modestly, but operating cash use increased substantially to $7.9 million from $5.6 million.
- There were no financing cash flows in Q1 2022, compared with $1.9 million of loan repayments in Q1 2021.
- Cash declined by $8.1 million during Q1 2022, from $144.5 million to $136.4 million.
- Stock-based compensation increased to $1.6 million from $0.9 million. Remaining unrecognized stock-based compensation cost was $14.0 million.
- Shares outstanding increased significantly year over year, contributing to the lower reported loss per share despite the continuing operating losses.
Guidance, outlook, commentary and risks
- Management expects existing cash resources to fund operating expenses and capital expenditures into the second half of 2024 based on current research and development plans. The company expects additional funding will be required to complete development and commercialize its candidates.
- The company planned to open U.S. CTX-009 clinical sites in Q2 2022 and begin dosing in Q3 2022. Management discussed a potential Phase 2/3 CTX-009 program in biliary tract cancer and a potential 2024 BLA filing, subject to clinical and regulatory outcomes.
- Interim CTX-009 data reported after quarter-end showed 24 patients dosed, 10 partial responses, 9 confirmed responses and a preliminary overall response rate of 42%. These data were preliminary and had not undergone a formal safety analysis.
- For CTX-471, management expected to complete the Phase 1 dose-expansion stage in Q3 2022. As of February 25, 2022, 38 evaluable patients produced a preliminary 8% overall response rate and 58% clinical benefit rate.
- Manufacturing supply-chain delays at Fujifilm delayed CTX-8371 GMP manufacturing. The campaign began in March 2022, with an IND submission target of Q1 2023.
- COVID-19-related supply constraints have delayed or may delay manufacturing and clinical trial timelines and may affect personnel, vendors, costs and material availability.
- Clinical and regulatory development risks include failure to demonstrate safety or efficacy, enrollment and manufacturing delays, changing regulatory requirements, inability to obtain approvals, competition and the need for substantial additional capital.
- The company may raise additional equity or debt or enter collaborations. Additional equity financing could dilute existing stockholders, while collaborations could require surrendering rights to technologies, programs or future revenues.
- A $6.0 million milestone payment to ABL Bio remains payable upon delivery of the final Phase 1 CTX-009 clinical report. Additional potential license and collaboration payments include $2.0 million under the Adimab agreement and $2.4 million of future Fujifilm-related expense and payments.
- Management concluded that disclosure controls and procedures were effective as of March 31, 2022, with no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Whether the $136.4 million cash balance and projected runway remain adequate after the planned CTX-009, CTX-471 and CTX-8371 development activities.
- Whether preliminary CTX-009 response and safety results are confirmed in a larger, formally analyzed clinical dataset.
- The timing, cost and regulatory status of the planned CTX-009 Phase 2/3 studies and potential 2024 BLA filing.
- Whether CTX-8371 manufacturing and IND-enabling activities remain on schedule following supply-chain delays.
- The timing and cash impact of the $6.0 million ABL Bio milestone and other collaboration obligations.
- The company’s rate of cash burn, need for additional financing and potential dilution from future capital raises.
- Whether CTX-471’s preliminary activity supports advancement into a subsequent clinical program.
- The extent to which COVID-19, supply-chain conditions, clinical enrollment or regulatory feedback could alter development timelines.